Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Jon C. Ogg | Nov 5, 2019 at 1:12 PM EST

After a 50% Drop, One Analyst Sees Bluebird Bio With Almost 50% Upside

On a day that the Dow Jones industrials and S&P 500 just hit all-time highs, many companies are not exactly…

Chris Lange | Nov 5, 2019 at 12:57 PM EST

Major Biotechs See Rising Tide in Short Interest

The October 15 short interest data has been compared with the previous report, and short interest in most of these…

Paul Ausick | Nov 4, 2019 at 1:21 PM EST

Deaths From Poor Diet Outnumber Those From Smoking, and Medical Schools Aren’t Helping

More people die every year from poor diet than from smoking, yet medical schools spend little time educating future doctors…

Jon C. Ogg | Nov 4, 2019 at 12:15 PM EST

After a 50% Drop, One Analyst Sees Bluebird Bio With Almost 50% Upside

On a day that the Dow Jones industrials and S&P 500 just hit all-time highs, many companies are not exactly…

Chris Lange | Nov 4, 2019 at 10:20 AM EST

Are Wright Medical Shareholders Getting Enough in the Stryker Acquisition?

Wright Medical Group shares exploded on Monday after it was announced that the firm would be acquired by Stryker.

Chris Lange | Nov 4, 2019 at 10:00 AM EST

Meet the Newest FDA Approval in the Fight Against Non-Cardia Gastric Cancer

Redhill Bio shares jumped early on Monday after the firm announced that the FDA approved Talicia for the treatment of…

Chris Lange | Oct 30, 2019 at 1:05 PM EDT

Multiple Sclerosis Treatment Wins Big FDA Approval

Biogen and Alkermes have announced that the FDA approved Vumerity for the treatment of relapsing forms of multiple sclerosis.

Chris Lange | Oct 29, 2019 at 4:20 PM EDT

Why Amgen Failed to Impress in Q3

When Amgen released its third-quarter financial results after the markets closed on Tuesday, the firm said that it had $3.66…

Chris Lange | Oct 29, 2019 at 12:40 PM EDT

Can Amgen Earnings Keep Up With Biogen?

Amgen is set to report its most recent quarterly results after the closing bell on Tuesday. Wall Street expectations are…

Chris Lange | Oct 29, 2019 at 10:20 AM EDT

Is This the Turnaround Pfizer and Merck Shareholders Have Been Waiting For?

Shares of Merck and Pfizer both got boosts after they reported their most recent quarterly results before the opening bell…

Chris Lange | Oct 28, 2019 at 1:25 PM EDT

Merck and Pfizer Earnings: What to Expect

Merck and Pfizer are set to report their most recent quarterly results before the opening bell tomorrow. Pfizer is one…

Chris Lange | Oct 25, 2019 at 10:45 AM EDT

It’s Not the FDA Holding Back This New Pneumonia Treatment

Melinta shares dropped on Friday even though the firm announced that the FDA has approved Baxdela (delafloxacin) for the treatment…

Chris Lange | Oct 25, 2019 at 10:05 AM EDT

Major Biotechs See Rising Tide in Short Interest

The October 15 short interest data has been compared with the previous report, and short interest in most of these…

Chris Lange | Oct 25, 2019 at 9:59 AM EDT

Short Sellers Can’t Make Up Their Minds on Big Pharma

The October 15 short interest data have been compared with the previous figures, and short interest moves in these selected…

Chris Lange | Oct 23, 2019 at 10:25 AM EDT

Eli Lilly Just Couldn’t Get It Together in Q3

Eli Lilly shares retreated after it released mixed third-quarter financial results before the markets opened on Wednesday.

1 … 79 80 81 82 83 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

After a 50% Drop, One Analyst Sees Bluebird Bio With Almost 50% Upside

Major Biotechs See Rising Tide in Short Interest

Deaths From Poor Diet Outnumber Those From Smoking, and Medical Schools Aren’t Helping

After a 50% Drop, One Analyst Sees Bluebird Bio With Almost 50% Upside

Are Wright Medical Shareholders Getting Enough in the Stryker Acquisition?

Meet the Newest FDA Approval in the Fight Against Non-Cardia Gastric Cancer

Multiple Sclerosis Treatment Wins Big FDA Approval

Why Amgen Failed to Impress in Q3

Can Amgen Earnings Keep Up With Biogen?

Is This the Turnaround Pfizer and Merck Shareholders Have Been Waiting For?

Merck and Pfizer Earnings: What to Expect

It’s Not the FDA Holding Back This New Pneumonia Treatment

Major Biotechs See Rising Tide in Short Interest

Short Sellers Can’t Make Up Their Minds on Big Pharma

Eli Lilly Just Couldn’t Get It Together in Q3

This High-Yield Bond ETF Offers Steady Cash Flow and Low Volatility

This Natural Resources ETF Has Silently Outperformed The S&P 500 Year-To-Date While Yielding 5%

XRP vs Solana vs Ethereum: Which Altcoin is the Best Buy for Upside Right Now?

39% of Americans Are Betting on Crypto and Prediction Markets Instead of Saving

A $300,000 Annuity Guarantees $1,900 a Month for Life, but Here Is What Retirees Are Giving Up

This High-Yield Bond ETF Offers Steady Cash Flow and Low Volatility

This Natural Resources ETF Has Silently Outperformed The S&P 500 Year-To-Date While Yielding 5%

Health and Healthcare Articles

All Health and Healthcare Articles

After a 50% Drop, One Analyst Sees Bluebird Bio With Almost 50% Upside

Major Biotechs See Rising Tide in Short Interest

Deaths From Poor Diet Outnumber Those From Smoking, and Medical Schools Aren’t Helping

After a 50% Drop, One Analyst Sees Bluebird Bio With Almost 50% Upside

Are Wright Medical Shareholders Getting Enough in the Stryker Acquisition?

Meet the Newest FDA Approval in the Fight Against Non-Cardia Gastric Cancer

Multiple Sclerosis Treatment Wins Big FDA Approval

Why Amgen Failed to Impress in Q3

Can Amgen Earnings Keep Up With Biogen?

Is This the Turnaround Pfizer and Merck Shareholders Have Been Waiting For?

Merck and Pfizer Earnings: What to Expect

It’s Not the FDA Holding Back This New Pneumonia Treatment

Major Biotechs See Rising Tide in Short Interest

Short Sellers Can’t Make Up Their Minds on Big Pharma

Eli Lilly Just Couldn’t Get It Together in Q3

This High-Yield Bond ETF Offers Steady Cash Flow and Low Volatility

This Natural Resources ETF Has Silently Outperformed The S&P 500 Year-To-Date While Yielding 5%

XRP vs Solana vs Ethereum: Which Altcoin is the Best Buy for Upside Right Now?

Featured Reads

39% of Americans Are Betting on Crypto and Prediction Markets Instead of Saving

A $300,000 Annuity Guarantees $1,900 a Month for Life, but Here Is What Retirees Are Giving Up